November 11th 2023
Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.
February 20th 2023
Brian Ramnaraign, MD, discusses the investigation of atezolizumab with tivozanib in castrate-resistant prostate cancer.
February 1st 2023
Brian Ramnaraign, MD, discusses the evaluation of atezolizumab plus tivozanib in a phase 1b/2 trial in patients with pancreatic, gallbladder, and bile duct cancers.
March 8th 2022
Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.
November 18th 2021
Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma.